Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response

Gavin Cloherty, Stephane Chevaliez, Christoph Sarrazin, Christine Herman, Vera Holzmayer, George Dawson, Benjamin Maasoumy, Johannes Vermehren, Heiner Wedemeyer, Jordan J Feld, Jean-Michel Pawlotsky, Gavin Cloherty, Stephane Chevaliez, Christoph Sarrazin, Christine Herman, Vera Holzmayer, George Dawson, Benjamin Maasoumy, Johannes Vermehren, Heiner Wedemeyer, Jordan J Feld, Jean-Michel Pawlotsky

Abstract

Approval of Ledipasvir/Sofosbuvir for the treatment of chronic hepatitis C (HCV) includes the truncation of therapy from 12 to 8 weeks in treatment naïve, non-cirrhotic patients with baseline HCV RNA levels <6 million IU/mL (6.8 log10 IU/mL). The aim of this study was to evaluate this clinical cutoff with a different widely used commercially available HCV RNA test. Results from samples tested prospectively with Roche High Pure TaqMan HCV 2.0 test (HPS) were compared to those tested retrospectively with the Abbott RealTime HCV RNA test (ART). Using 6 million IU/mL as the cut-off, pre-treatment results were concordant in 70.4% of cases. When results with the same test measured at screening and baseline, clinical decisions could be impacted in 14.4% and 6.2% of cases for HPS and ART respectively. Using only HCV RNA cutoff of 6 million IU/mL, 29.55% of subjects would receive a different and potentially incorrect treatment duration based solely on HCV RNA test method used. A further 6-14% of subjects would have treatment decision change based on the day the sample was taken.

Trial registration: ClinicalTrials.gov NCT01716585.

Conflict of interest statement

Gavin Cloherty, Kevin Cheng, Christine Herman, Vera Holzmayer, George Dawson and John Hackett are employees and shareholders of Abbott Laboratories. Heiner Wedemeyer has received honoraria for consulting or speaking engagements from Abbott, Abbvie, Biolex, Bristol-Myers Squibb, Boehringer Ingelheim, Eiger Pharmaceuticals, Falk Foundation, Gilead Sciences, ITS, JJ/Janssen-Cilag/Janssen TE, Medgenics, Merck/ Schering-Plough, Novartis, Novaria, Roche, Roche Diagnostics, Siemens, Transgene and ViiV. Jean-Michel Pawlotsky has received research grants from Gilead Sciences and has served as an advisor fror Abbott, Abbvie, Achillon, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Idenix, Janssen, Merck, Novartis and Roche. Christoph Sarrazin has received speaker fees, advisory boards and research support from Abbvie, Roche, Siemens and Qiagen. Stephen Chevaliez has received research grants from Gilead Sciences and has served as an advisor for Gilead Sciences and Roche Pharmaceuticals. Jordan Feld has received consulting fees from Abbvie, Abbott, BMS, Gilead, Janssen, Merck, Theravance. Research support from Abbvie, Abbott, BI, BMS, Gilead, Janssen, Merck, Santaris. Benjamin Maasoumy has received speaker and/or consulting fees from Abbott Molecular, Roche, MSD/Merck, BMS, Fujirebio, Janssen-Cilaq. Research support from Roche and Abbott Molecular. Travel grants from Janssen-Cilaq and Gilead. Johannes Vermehren has received consulting and lecture fees from Abbott, AbbVie, Bristol-Myers Squibb, Covidien, Gilead.

Figures

Figure 1. Breakdown of samples tested with…
Figure 1. Breakdown of samples tested with both Roche High Pure HCV RNA 2.0 and Abbott RealTime HCV RNA tests by timepoint.
Figure 2. Least-Squares regression between Abbott RealTime…
Figure 2. Least-Squares regression between Abbott RealTime HCV vs Roche HPS/TaqMan 2.0 for all data points within the dynamic range of both assays.
Clinically significant discordant results are found in red box.
Figure 3. Bland Altman Bias Plot Abbott…
Figure 3. Bland Altman Bias Plot Abbott RealTime HCV vs Roche HPS/TaqMan 2.0 for samples with viral load 25 IU/mL or Greater (n = 1011).
The mean difference between the two assays was −0.50 (95% Confidence Interval: −0.53 and −0.48; p 10 IU/mL HCV RNA.
Figure 4. ROC analysys of all available…
Figure 4. ROC analysys of all available pre-treatment viral load measurements with both Roche HPS/TaqMan 2.0 HCV and Abbott RealTime HCV assays.
For this analysis Roche HPS/TaqMan 2.0 HCV was considered gold standard.
Figure 5. Samples with Roche HPS/TaqMan 2.0…
Figure 5. Samples with Roche HPS/TaqMan 2.0 HCV results falling within log intervals of the assays dynamic range were adjusted based on the calculated negative bias observed with the Abbott RealTime HCV test.
The linear regression of mean expected results compared to the mean expected results adjusted for bias.
Figure 6
Figure 6
(a) Percent detected by Abbott RealTime HCV (ART) and Roche HPS/TaqMan 2.0 HCV using 25 IU/mL as cut-off. DBD = Double Blind Day; OLW = Open Label Week; PSTW = Post Treatment Week. (b) Percent detected by Abbott RealTime HCV (ART) and Roche HPS/TaqMan 2.0 HCV using 100 IU/mL as cut-off. DBD = Double Blind Day; OLW = Open Label Week; PSTW = Post Treatment Week.

References

    1. Gower E. et al.. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61, 45–57 (2014).
    1. Wise M. et al.. Changing trends in hepatitis C–related mortality in the United States, 1995–2004. Hepatology 47, 1128–1135 (2008).
    1. The Global Burden of Hepatitis C Working Group. The Global Burden of Hepatitis C. J Clinical Pharmacology 44, 20–29 (2004).
    1. Afdhal N. et al.. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370, 1483–1493 (2014).
    1. Afdhal N. et al.. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370, 1889–1898 (2014).
    1. Feld J. J. et al.. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370, 1594–1603 (2014).
    1. Kowdley K. V. et al.. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370, 1879–1888 (2014).
    1. Kwo P. et al.. A Phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1. J Hepatol 62, S270 (2015).
    1. Wyles D. et al.. Daclatasvir Plus Sofosbuvir for Treatment of HCV Genotypes 1–4 in HIV-HCV Coinfection: The ALLY-2 Study. J Hepatol S263 (2015).
    1. Zeuzem S. et al.. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 370, 1604–1614 (2014).
    1. Kowdley K. V. et al.. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370, 1879–1888 (2014).
    1. Prescribing information HARVONI (ledipasvir and sofosbuvir) tablets, for oral use. Initial US Approval2014. . Accessed on march 8th 2016).
    1. European Association for the Study of the Liver EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol Epub ahead of print (2015).
    1. Colucci G. et al.. Improved COBAS TaqMan hepatitis C virus test (Version 2.0) for use with the High Pure system: enhanced genotype inclusivity and performance characteristics in a multisite study. J Clin Microbiol 45, 3595–3600 (2007).
    1. Fevery B. et al.. HCV RNA quantification with different assays: implications for protease inhibitor-based response-guided therapy. Antivir Ther 19, 559–567 (2014).
    1. Sarrazin C. et al.. Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J Clin Microbiol 44, 729–737 (2006).
    1. Sidharthan S. et al.. Utility of Hepatitis C Viral Load Monitoring On Directly Acting Antiviral Therapy. Clin Infect Dis 60(12), 1743–1751 (2015).
    1. Buggisch P. et al.. Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in Genotype 1 Treatment-Naïve Non-Cirrhotic Patients with HCV viral load (VL) <6 millionIU/ml; A comparative Analysis of the phase-3 ION-3 Data to Real-World Effectiveness. In abstracts and posters from the International Liver Congress, Barcelona Spain, April 14–17 2016.
    1. Vermehren J. et al.. Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. Clinical Infectious Disease 15, 62(10), 1228–1234 (2016).
    1. Vermehren J. et al.. Multi-Center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. J Clin Virol 52, 133–137 (2011).
    1. Fevery B. et al.. HCV RNA quantification with different assays: implications for protease inhibitor-based response-guided therapy. Antivir Ther 19, 559–567. 26 (2014)
    1. Sarrazin C. et al.. Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy. J Virol Methods 214, 29–32 (2015).
    1. Maasoumy B. et al.. Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. Plos One 12, 9:e110857 (2014).
    1. Cloherty G. et al.. Hepatitis C Virus RNA Assay Sensitivity Impacts the Management of Patients Treated with Direct-Acting Antivirals. Antiviral Therapy 10.3851/IMP 2810 (2014).
    1. Sarrazin C. et al.. An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay. J Clin Micro. 53(4), 1264–1269 (2015).
    1. Zitzer H. et al.. Second-generation Cobas AmpliPrep/Cobas TaqMan HCV quantitative Test for viral load monitoring: a novel dual-probe assay design. J Clin Micro 51, 571–577 (2013).
    1. Pyne M. T. et al.. Evaluation of the Abbott Investigational Use Only RealTime Hepatitis C Virus (HCV) Assay and Comparison to the Roche TaqMan HCV Analyte-Specific Reagent Assay. J Clin Micro. 2872–2878 (2009).
    1. Heidi LaRue et al.. Performance of the Abbott RealTime and Roche COBAS Taqman HCV Assays for quantification of Hepatitic C Virus Genotypes. J Clin Micro. 50(5), 1769–1772 (2012).
    1. O’Brien T. R., Feld J. J., Kottilil S. & Pfeiffer R. M. No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL. Hepatology 63(1), 28–30 (2016).
    1. Chevaliez S., Bouvier-Alias M. & Pawlotsky J. M. Performance of the Abbott real-time PCR assay using m2000sp and m2000rt for hepatitis C virus RNA quantification. J Clin Microbiol 47, 1726–1732 (2009).

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren